abstract |
The present invention relates to the treatment of diseases characterized by overexpression of ErbB2. More specifically, the present invention relates to a method of treating a human patient diagnosed with cancer that overexpresses ErbB2, or a patient suspected of having such cancer, by administering an anti-ErbB2 antibody in combination with a chemotherapeutic agent other than anthracycline such as doxorubicin or epirubicin will be. |